Table 2 Correlation between mast cell infiltration and clinicopathologic factors
Clinicopathologic factors | Number of patients (%) | Mast cell count Mean (s.e.) a | P -value |
|---|---|---|---|
Age (years) | |||
<70 | 51 (49%) | 20.35 (13.25) | NS |
⩾70 | 53 (51%) | 20.11 (11.83) | |
PSA b (ng/ml) | |||
<20 | 54 (51.9%) | 18.59 (10.08) | NS |
⩾20 | 50 (48.1%) | 21.74 (14.29) | |
Gleason score (GS) | |||
GS⩽6 | 49 (44.2%) | 15.80 (8.03) | <0.05c |
GS=7 | 29 (27.9%) | 20.98 (13.94) | <0.001d |
GS⩾8 | 26 (25.0%) | 27.74 (14.25) | <0.05e |
Clinical T stage | |||
⩽T2 | 66 (63.4%) | 17.30 (8.26) | <0.001 |
⩾T3 | 38 (36.5%) | 25.10 (16.39) | |
PSA failure | |||
+ | 30 (28.8%) | 27.56 (15.70) | <0.001 |
− | 74 (71.2%) | 16.67 (8.69) | |
